-
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
- Source: Pipelinereview
- 529
- April 13, 2018
-
Major Medical Associations Feud Over Diabetes Guidelines
- Source: NPR
- 532
- March 6, 2018
-
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
